Featured Issue Briefs
The Battle on the Home Front: Jonathan Gadsden's Story
Marine Lance Corporal's story reflects the growing need for new antibiotics that can treat dangerous diseases, against which most drugs are useless. Read More
Facilitating Medical Device Innovation: De Novo Reform
The de novo process -- which requests lower-risk reclassification of medical devices and entry into the marketplace -- as it exists now is not achieving its purpose and has instead added unnecessary and time-consuming requirements. Read More
Food Products Recalled by FDA
Since President Obama signed the FDA Food Safety Modernization Act into law, at least 149 FDA-regulated food products have been recalled due to potential pathogenic contamination. Read More
More Issue Briefs
| Date | Issue Briefs | Topic |
|---|---|---|
| Mar 1, 2012 |
When Multiple Bugs Strike: The Story of Alice BrennanA healthy immune system may be all the protection someone needs to overcome a bacterial infection, but once one disease takes hold, it may beget more illnesses. Such is often the case with Clostridium difficile, a potentially deadly bacterium that can flourish in the wake of other infections. Senior citizens, such as Alice Brennan, are particularly vulnerable and serve as a reminder that new and powerful antibiotics are needed as protection from dangerous bacterial threats. More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Superbug ThreatAs Drug-resistant bacteria spread, the pipeline for antibiotics is drying up More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Threat of Multidrug-Resistant Infections to the U.S. MilitaryExpert Testimony, Research, and Commentary Learn More “MDRO multidrug resistant organism infections have become an international health problem during the past several decades and now pose a challenge to the care of our wounded military personnel.” — D. Hospenthal More info |
Antibiotic Innovation |
| Jan 2, 2012 |
Patient Story: Jamel Sawyer: A Young Man Fights MRSAOne of the most notorious multidrug-resistant superbugs, MRSA is responsible for an estimated 19,000 deaths and 360,000 hospitalizations each year in this country. Jamel’s story illustrates the twin dangers presented by emerging multidrug-resistant bacterial infections and the waning effectiveness and availability of drugs to treat them. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
National Headlines Reporting on the Need for New, Lifesaving AntibioticsNational and international headlines warn that multidrug-resistant superbugs are on the rise and the pipeline of new antibiotics is running dry. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
What Leading Experts are Saying about Emerging Drug-Resistant Infections and the Need for New Drugs to Treat ThemLegislators, regulators, scientists and academics agree: we are running out of antibiotics to treat drug-resistant infections—and we need new ones now. Here is what leading voices are saying about how economic, scientific and regulatory factors are impeding the development of new antibiotics, and what we can do about it. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
Bill Summary: The Generating Antibiotic Incentives Now Act (H.R. 2182)The Generating Antibiotic Incentives Now (GAIN) Act of 2011 (H.R. 2182) seeks to create incentives to encourage the development of products to treat, prevent, detect and diagnose antibiotic-resistant infections. It extends the length of time an approved drug is free from competition and clarifies the regulatory pathway for new antibiotics. More info |
Antibiotic Innovation |
| May 9, 2013 |
Pew Testimony on the Safety of Compounding PharmaciesThe U.S. Senate Committee on Health, Education, Labor and Pensions held a hearing on May 9 entitled "Pharmaceutical Compounding: Proposed Legislative Solution." Pew's Allan Coukell, a pharmacist and drug safety expert, testified on the need to strengthen oversight of the compounding industry. More info |
|
| Apr 9, 2013 |
Pew Comments on Centers for Medicaid and Medicare Services' Information Collection Activities Draft GuidanceThe Pew Charitable Trusts appreciates this opportunity to submit comments to CMS's "Information Collection Activities" draft guidance. We suggest that both the research and non-research payment templates be modified in order to make it easier for consumers to identify which drugs, devices, biologicals, or medical supplies are associated with particular transfers of value. More info |
|
| Apr 4, 2013 |
Pew Comments on Draft Recommendations for Meaningful Use, Stage 3The Pew Charitable Trusts submitted comments on preliminary recommendations regarding Stage 3 meaningful use objectives and standards for electronic health records (EHRs) to the Office of the National Coordinator for Health Information Technology. These comments follow remarks at recent meetings of the Health Information Technology (HIT) Policy Committee and HIT Standards Committee. More info |
